Anticoagulation Management of Patients with Antiphospholipid Syndrome Undergoing Cardiopulmonary Bypass in Cardiac Surgery: Challenges and Current Strategies

Abstract

The antiphospholipid syndrome (APS) is a complex autoimmune disease that causes a state of hypercoagulability that can result in recurrent venous and arterial thromboses. APS may lead to cardiac manifestations requiring cardiac surgery with cardiopulmonary bypass (CPB). Perioperative anticoagulation management in APS patients is complex. This complexity arises from both the prothrombotic nature of APS and the interference of antiphospholipid antibodies (aPLs) with phospholipid-dependent coagulation assays like activated clotting time. Given that current literature on CPB management in APS patients is largely limited to isolated case reports and lacks a comprehensive synthesis, this review summarizes the cardiac manifestations of APS, challenges posed by CPB, and current strategies for intraoperative anticoagulation management, including heparin dosing, anticoagulation monitoring methods, and protamine reversal practices. We further highlight gaps in evidence and propose a practical three-category framework for managing aPL-positive patients undergoing CPB.

Keywords

antiphospholipid syndrome - cardiopulmonary bypass - anticoagulation management

^‡ These authors contributed equally to the article.

Publication History

Received: 19 November 2025

Accepted: 27 January 2026

Accepted Manuscript online:
30 January 2026

Article published online:
20 February 2026

• References

• 1 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
• 2 Favaloro EJ, Pasalic L. Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants. Res Pract Thromb Haemost 2022; 6 (02) e12676
• 3 Denas G, Jose SP, Bracco A, Zoppellaro G, Pengo V. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2015; 14 (03) 214-222
• 4 Lee ESH, Narasimhan U, Kofidis T, Ti LK. Difficulties with the use of thromboelastometry in a patient with antiphospholipid syndrome undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2015; 29 (04) 1016-1020
• 5 Meroni PL, Borghi MO. Antiphospholipid antibody assays in 2021: looking for a predictive value in addition to a diagnostic one. Front Immunol 2021; 12: 726820
• 6 Koniari I, Siminelakis SN, Baikoussis NG, Papadopoulos G, Goudevenos J, Apostolakis E. Antiphospholipid syndrome; its implication in cardiovascular diseases: a review. J Cardiothorac Surg 2010; 5: 101
• 7 Schreiber K, Aguilera S, Amengual O. et al. Diagnostic, research, and real-life effect of the 2023 EULAR-ACR classification criteria for antiphospholipid syndrome. Lancet Rheumatol 2025; 7 (05) e368-e376
• 8 Barbhaiya M, Zuily S, Naden R. et al; ACR/EULAR APS Classification Criteria Collaborators. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis 2023; 82 (10) 1258-1270
• 9 Barbhaiya M, Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?. Curr Rheumatol Rep 2011; 13 (01) 59-69
• 10 Otomo K, Atsumi T, Amengual O. et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012; 64 (02) 504-512
• 11 Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the global anti-phospholipid syndrome score. Rheumatology (Oxford) 2013; 52 (08) 1397-1403
• 12 Radin M, Sciascia S, Erkan D. et al; APS ACTION. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Semin Arthritis Rheum 2019; 49 (03) 464-468
• 13 Di Minno MND, Scalera A, Tufano A. et al. The association of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies. Atherosclerosis 2018; 278: 60-65
• 14 Kwon OC, Ha JW, Park MC, Park YB, Lee SW. Development of a new scoring system for predicting recurrent thrombosis in patients with antiphospholipid syndrome. Adv Rheumatol 2025; 65 (01) 40
• 15 Tektonidou MG, Andreoli L, Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78 (10) 1296-1304
• 16 Kolitz T, Shiber S, Sharabi I, Winder A, Zandman-Goddard G. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol 2019; 10: 941
• 17 Cervera R, Serrano R, Pons-Estel GJ. et al; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74 (06) 1011-1018
• 18 Morel N, Le Guern V, Mouthon L, Piette JC, Costedoat-Chalumeau N. [Heart involvement in systemic lupus erythematosus and antiphospholipid syndrome.]. Rev Med Interne 2022; 43 (11) 645-648
• 19 Ahmed O, King NE, Qureshi MA. et al. Non-bacterial thrombotic endocarditis: a clinical and pathophysiological reappraisal. Eur Heart J 2025; 46 (03) 236-249
• 20 Osula S, Bell GM, Hornung RS. Acute myocardial infarction in young adults: causes and management. Postgrad Med J 2002; 78 (915) 27-30
• 21 Takeuchi S, Obayashi T, Toyama J. Primary antiphospholipid syndrome with acute myocardial infarction recanalised by PTCA. Heart 1998; 79 (01) 96-98
• 22 Hegde VA, Vivas Y, Shah H. et al. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome–a case-series. Heart Lung Circ 2007; 16 (06) 423-427
• 23 Zuily S, Wahl D. Pulmonary hypertension in antiphospholipid syndrome. Curr Rheumatol Rep 2015; 17 (01) 478
• 24 Lockshin M, Tenedios F, Petri M. et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 2003; 12 (07) 518-523
• 25 Manning JE, Arachchillage DJ. Dilemmas in the diagnosis and management of antiphospholipid syndrome. J Thromb Haemost 2024; 22 (08) 2156-2170
• 26 Sharma VK, Chaturvedi R, Manoj Luthra V. Antiphospholipid syndrome, cardiac surgery and cardiopulmonary bypass. Ann Card Anaesth 2011; 14 (02) 146-149
• 27 Berkun Y, Elami A, Meir K, Mevorach D, Naparstek Y. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg 2004; 127 (02) 414-420
• 28 Colli A, Mestres CA, Espinosa G. et al. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardiothorac Surg 2010; 37 (01) 154-158
• 29 Massoudy P, Cetin SM, Thielmann M. et al. Antiphospholipid syndrome in cardiac surgery-an underestimated coagulation disorder?. Eur J Cardiothorac Surg 2005; 28 (01) 133-137
• 30 Eviatar T, Niznik S, Elkayam O. et al. Heart valve surgery in antiphospholipid syndrome patients-morbidity and mortality. Life (Basel) 2023; 13 (04) 891
• 31 Horton S, Augustin S. Activated clotting time (ACT). Methods Mol Biol 2013; 992: 155-167
• 32 Mehta TP, Smythe MA, Mattson JC. Strategies for managing heparin therapy in patients with antiphospholipid antibody syndrome. Pharmacotherapy 2011; 31 (12) 1221-1231
• 33 Parepalli A, Sarode R, Kumar S, Nelakuditi M, Kumar MJ. Antiphospholipid syndrome and catastrophic antiphospholipid syndrome: a comprehensive review of pathogenesis, clinical features, and management strategies. Cureus 2024; 16 (08) e66555
• 34 Uthman I, Noureldine MHA, Ruiz-Irastorza G, Khamashta M. Management of antiphospholipid syndrome. Ann Rheum Dis 2019; 78 (02) 155-161
• 35 Cartwright BL, Bean M, Cooper JO. Lupus anticoagulant, antiphospholipid syndrome and cardiac surgery. Anaesth Intensive Care 2010; 38 (02) 364-369
• 36 Yoshinaga K, Otsuka Y, Furukawa T, Amitani S, Kimura N, Sanui M. Correlation between activated clotting time monitoring and heparin concentration measurement in a patient with antiphospholipid syndrome during cardiac valve surgery: a case report. JA Clin Rep 2021; 7 (01) 24
• 37 Miyazawa K, Otsuka Y, Ishiguro Y. Wide discrepancies in activated clotting times measured by two devices were detected for a patient with lupus anticoagulant in a cardiac surgery. Perfusion 2016; 31 (08) 709-710
• 38 Katunaric B, Boettcher B. Walking the tightrope: anticoagulation management of patients with antiphospholipid syndrome and immune thrombocytopenic purpura undergoing mitral valve replacement with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2024; 38 (11) 2731-2736
• 39 Dornan RIP. Acute postoperative biventricular failure associated with antiphospholipid antibody syndrome. Br J Anaesth 2004; 92 (05) 748-754
• 40 East CJ, Clements F, Mathew J, Slaughter TF. Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. Anesth Analg 2000; 90 (05) 1098-1101
• 41 Nakajima T, Enomoto Y, Ishigaki M. et al. Perioperative anticoagulation management during aortic valve replacement complicated by antiphospholipid syndrome. J Card Surg 2017; 32 (10) 633-635
• 42 Hogan WJ, McBane RD, Santrach PJ. et al. Antiphospholipid syndrome and perioperative hemostatic management of cardiac valvular surgery. Mayo Clin Proc 2000; 75 (09) 971-976
• 43 Ducart AR, Collard EL, Osselaer JC, Broka SM, Eucher PM, Joucken KL. Management of anticoagulation during cardiopulmonary bypass in a patient with a circulating lupus anticoagulant. J Cardiothorac Vasc Anesth 1997; 11 (07) 878-879
• 44 Jervis K, Senthilnathan V, Lerner AB. Management of a patient with lupus anticoagulant and antiphospholipid syndrome for off-pump coronary artery bypass grafting using the Hepcon system. Anesth Analg 2009; 108 (04) 1116-1119
• 45 Lango R, Pawlaczyk R, Raszeja-Specht A. et al. Aortic valve replacement and perioperative management in hemodialyzed patient with antiphospholipid syndrome. Int J Artif Organs 2004; 27 (01) 69-73
• 46 Babin JL, Traylor KL, Witt DM. Laboratory monitoring of low-molecular-weight heparin and fondaparinux. Semin Thromb Hemost 2017; 43 (03) 261-269
• 47 Cohen H, Efthymiou M, Devreese KMJ. Monitoring of anticoagulation in thrombotic antiphospholipid syndrome. J Thromb Haemost 2021; 19 (04) 892-908
• 48 Arachchillage DJ, Crossette-Thambiah C, Laffan M. Lupus anticoagulant and cardiopulmonary bypass. Semin Thromb Hemost 2022; 48 (05) 628-630
• 49 Pagano D, Milojevic M, Meesters MI. et al. 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery. Eur J Cardiothorac Surg 2018; 53 (01) 79-111
• 50 Nakajima T, Kato H, Mathis BJ, Hiramatsu Y, Sakamoto H. TEG improves anticoagulation management during cardiopulmonary bypass complicated by antiphospholipid syndrome. J Card Surg 2020; 35 (06) 1354-1356
• 51 Cameron M, Al Aamri I. Pitfalls of commonly used anticoagulation monitoring techniques in antiphospholipid syndrome during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2021; 35 (02) 585-588
• 52 Gorki H, Malinovski V, Stanbridge RDL. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg 2008; 33 (02) 168-181
• 53 Sheikh F, Lechowicz A, Setlur R, Rauch A, Dunn H. Recognition and management of patients with antiphospholipid antibody syndrome undergoing cardiac surgery. J Cardiothorac Vasc Anesth 1997; 11 (06) 764-766
• 54 Cho H, Jeon Y, Hong DM, Kim HJ, Min JJ. Anesthetic management of antiphospholipid syndrome patients who underwent cardiac surgery: three cases report. Korean J Anesthesiol 2014; 66 (02) 164-168
• 55 Malviya SA, Deng Y, Gilani SO, Hendon AA, Nikolaidis MA, Moseley MS. Management of perioperative anticoagulation in a patient with antiphospholipid antibody syndrome undergoing cardiac surgery: a case report. Ann Card Anaesth 2022; 25 (02) 206-209
• 56 Weiss S, Nyzio JB, Cines D. et al. Antiphospholipid syndrome: intraoperative and postoperative anticoagulation in cardiac surgery. J Cardiothorac Vasc Anesth 2008; 22 (05) 735-739
• 57 Despotis GJ, Joist JH, Goodnough LT, Santoro SA, Spitznagel E. Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements. J Thorac Cardiovasc Surg 1997; 113 (03) 611-613
• 58 Despotis GJ, Summerfield AL, Joist JH. et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108 (06) 1076-1082
• 59 Greco K, Varelmann D, Patel J. Anesthetic management of a jehovah's witness patient for coronary artery bypass grafting with antiphospholipid antibody syndrome and renal transplant. Semin Cardiothorac Vasc Anesth 2024; 28 (03) 177-180
• 60 Hoppensteadt DA, Walenga JM. The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2008; 22 (01) 1-18 , v
• 61 Tun NT, Krishnamurthy M, Snyder R. Catastrophic antiphospholipid syndrome and heparin-induced thrombocytopenia-related diseases or chance association?. Blood Coagul Fibrinolysis 2015; 26 (02) 214-219
• 62 Alpert D, Mandl LA, Erkan D, Yin W, Peerschke EI, Salmon JE. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis 2008; 67 (03) 395-401
• 63 Koster A, Erdoes G, Nagler M, Birschmann I, Alberio L. How would we treat our own heparin-induced thrombocytopenia during cardiac surgery?. J Cardiothorac Vasc Anesth 2021; 35 (06) 1585-1593
• 64 Grubb KJ, Salehi P, Chedrawy EG. Bivalirudin: alternative anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. Recent Pat Cardiovasc Drug Discov 2010; 5 (01) 20-24
• 65 Cain RL, Spiess BD, Nelson M, Deanda Jr A, McCarthy HL, Green JA. Bivalirudin anticoagulation for a patient with hypercoagulable immune syndromes undergoing mitral valve surgery. Ann Thorac Surg 2006; 81 (06) 2308-2310
• 66 Leissner KB, Ketchedjian A, Crowley R, Ortega R, Hesselvik JF, Shemin RJ. Deep hypothermic circulatory arrest and bivalirudin use in a patient with heparin-induced thrombocytopenia and antiphospholipid syndrome. J Card Surg 2007; 22 (01) 78-82
• 67 Ibrahim W, Nakia H, Stephen M, Bruce S, Bryan W, William P. A patient with remote heparin-induced thrombocytopenia and antiphospholipid syndrome requiring cardiopulmonary bypass: do current guidelines apply?. Semin Cardiothorac Vasc Anesth 2019; 23 (02) 256-260
• 68 Salmi L, Elalamy I, Leroy-Matheron C, Houel R, Thébert D, Duvaldestin P. [Thrombosis of a cardiopulmonary bypass circuit despite recommended hypocoagulation with danaparoid during the acute phase of type II heparin-induced thrombocytopenia]. Ann Fr Anesth Réanim 2006; 25 (11–12): 1144-1148
• 69 Simon ER, Rakholia M, McHenry ML. et al. Cardiac surgery in a patient with antiphospholipid syndrome and heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 2022; 36 (04) 1196-1206
• 70 Kamath PBRD, Braham DL, Arachchillage DJ, Loja D. Lupus anticoagulant and valvular cardiac surgery. Perfusion 2025; 40 (06) 1495-1498
• 71 Devreese KMJ, de Groot PG, de Laat B. et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18 (11) 2828-2839
• 72 Saito S, Ikeguchi H, Yamamoto H, Koike A, Yamaguchi K, Takeuchi E. Does antiphospholipid antibody syndrome affect bioprosthetic heart valve? Midterm echocardiographic report. Jpn J Thorac Cardiovasc Surg 2005; 53 (01) 36-38
• 73 Rawat SKS, Mehta Y, Vats M, Mishra Y, Khurana P, Trehan N. Anesthetic management of right atrial mass removal and pulmonary artery thrombectomy in a patient with primary antiphospholipid antibody syndrome. Ann Card Anaesth 2010; 13 (01) 39-43
• 74 Brownstein L, Bartholomew TP, Silver DG, Berry CM. A case report of mitral valve replacement in a patient with lupus antibody syndrome. Perfusion 2003; 18 (06) 373-376
• 75 Mishra PK, Khazi FM, Yiu P, Billing JS. Severe antiphospholipid syndrome and cardiac surgery: Perioperative management. Asian Cardiovasc Thorac Ann 2016; 24 (05) 473-476
• 76 Seki T, Shingu Y, Sugiki H. et al. Anticoagulation management during cardiopulmonary bypass in patients with antiphospholipid syndrome. J Artif Organs 2018; 21 (03) 363-366
• 77 Ural K, Edelson J. Antiphospholipid syndrome and cardiac bypass: the careful balance between clotting and bleeding. J Extra Corpor Technol 2021; 53 (01) 46-49